drugset / Trial / NCT07349537
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.
Timeline
- Start
- 2026-01-08
- Primary completion
- 2028-04
- Completion
- 2028-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | — | Intravenous |
| Subject | RMC-5127 | Unknown | — | Oral |
| Subject | daraxonrasib | Small molecule | — | Oral |